Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) has earned an average rating of “Buy” from the nine brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $13.38.

A number of research analysts recently commented on ADAP shares. ValuEngine upgraded Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, December 31st. BidaskClub upgraded Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 1st. Finally, Zacks Investment Research upgraded Adaptimmune Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a research report on Monday, January 7th.

A number of institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG grew its position in Adaptimmune Therapeutics by 1,681,328.6% in the fourth quarter. Deutsche Bank AG now owns 117,700 shares of the biotechnology company’s stock valued at $676,000 after acquiring an additional 117,693 shares during the last quarter. Squarepoint Ops LLC bought a new position in Adaptimmune Therapeutics in the fourth quarter valued at about $622,000. Orbimed Advisors LLC grew its position in Adaptimmune Therapeutics by 102.6% in the fourth quarter. Orbimed Advisors LLC now owns 1,350,655 shares of the biotechnology company’s stock valued at $7,766,000 after acquiring an additional 684,062 shares during the last quarter. D. E. Shaw & Co. Inc. bought a new position in Adaptimmune Therapeutics in the fourth quarter valued at about $1,231,000. Finally, Baillie Gifford & Co. grew its position in Adaptimmune Therapeutics by 8.2% in the fourth quarter. Baillie Gifford & Co. now owns 3,699,521 shares of the biotechnology company’s stock valued at $21,272,000 after acquiring an additional 281,894 shares during the last quarter. Hedge funds and other institutional investors own 66.02% of the company’s stock.

Shares of NASDAQ ADAP traded up $0.05 during mid-day trading on Wednesday, reaching $4.29. The company had a trading volume of 261,800 shares, compared to its average volume of 275,182. Adaptimmune Therapeutics has a one year low of $3.55 and a one year high of $14.63. The stock has a market capitalization of $443.89 million, a P/E ratio of -4.47 and a beta of 1.31.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Read More: How to Calculate Compound Annual Growth Rate (CAGR)

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.